Targeted Oncology™ brings you Targeted Talks, a monthly podcast featuring discussions with academic and community oncologists surrounding advancements in cancer research and best practices for patient management.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Lessons from Real-World Cases of Small Cell Lung Cancer
In season 4, episode 12 of Targeted Talks, Federico Albrecht, MD, gives and account of 2 cases of patients with small cell lung cancer and how these patients were treated.
Social Determinants of Health Impacting Oncology Today
In season 4, episode 11 of Targeted Talks, Krisda Chaiyachati, MD, MPH, MSHP, discusses the social determinants of health for patients with cancer and key challenges for patients, like transportation insecurity.
Insights on the Use of Elacestrant in Previously-Treated, HER2- Metastatic Breast Cancer
Recommendations for Treating Central Nervous System Cancers
In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.
Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy
In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.
Pushing Forward With Molecularly-Driven Precision Medicine in Endometrial Cancer
In season 4, episode 8 of Targeted Talks, Ruchi Garg, MD, discusses treatment approaches for endometrial cancer now and in the near future.
Exciting Activity in Chronic Lymphocytic Leukemia
In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Advancing the Treatment of Alveolar Soft Part Sarcoma
In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.
Understanding and Treating Mucosal Melanoma
In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.
Hitting New Targets in Metastatic Prostate Cancer
In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.
The Importance of Trastuzumab Deruxtecan in HER2+ Breast Cancer Treatment
In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.
Unpacking the Latest Research in Gastrointestinal Cancers
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
A More Precise Approach to Small Cell Lung Cancer Treatment
In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.
Special Episode: Managing Cardiotoxicity from ICI Therapy in Patients With Cancer
In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, and Chris Fine, MD, FACC, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.
Treating HER2-Positive Beast Cancer in the Community Setting
In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.
The Evolution of Endometrial Cancer Treatment
In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
The Road to Improving Diffuse Large B-Cell Lymphoma Treatment
In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.
Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia
In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.
Unpacking the New Recommendations for Early-Stage Breast Cancer Management
In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.
Advances and Pending Innovations in the Treatment of Sarcoma
In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.
A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
Treating Sarcoma With a Multidisciplinary Approach
In season 2, episode 10 of Targeted Talks, Sandra P. D'Angelo, MD, and Katherine Poruk, MD, discuss frontline treatment practices in the sarcoma space.
Sequencing Therapy for Metastatic Castration-Resistant Prostate Cancer
In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.
New Targeted Therapies in Renal Cell Carcinoma
In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.
Recent Developments in Immunotherapy for Melanoma
In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.
Modern Strategies Improving Immunotherapy in Cancer
Jason Luke, MD, leads a discussion with Sandip Patel, MD, about the present and future of immunotherapy in cancer.
2 Clarke Drive Cranbury, NJ 08512